End-of-day quote
Shenzhen S.E.
03:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
18.82
CNY
|
+9.55%
|
|
+13.99%
|
+12.97%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,367
|
7,742
|
7,390
|
11,167
|
8,741
|
6,336
|
Enterprise Value (EV)
1 |
5,161
|
7,372
|
6,903
|
10,838
|
8,533
|
5,866
|
P/E ratio
|
20.4
x
|
38.2
x
|
-15.1
x
|
104
x
|
32.1
x
|
37
x
|
Yield
|
1.83%
|
1.01%
|
1.06%
|
0.68%
|
0.66%
|
1.2%
|
Capitalization / Revenue
|
1.78
x
|
2.77
x
|
2.49
x
|
3.56
x
|
2.49
x
|
1.79
x
|
EV / Revenue
|
1.72
x
|
2.64
x
|
2.33
x
|
3.45
x
|
2.43
x
|
1.66
x
|
EV / EBITDA
|
8
x
|
12.1
x
|
13.1
x
|
24.5
x
|
13.7
x
|
11.2
x
|
EV / FCF
|
-3,242
x
|
31.6
x
|
28.7
x
|
1,121
x
|
74
x
|
23.3
x
|
FCF Yield
|
-0.03%
|
3.16%
|
3.48%
|
0.09%
|
1.35%
|
4.28%
|
Price to Book
|
1.34
x
|
1.9
x
|
2.15
x
|
3.29
x
|
2.42
x
|
1.72
x
|
Nbr of stocks (in thousands)
|
3,93,152
|
3,90,026
|
3,87,903
|
3,83,875
|
3,83,875
|
3,80,338
|
Reference price
2 |
13.65
|
19.85
|
19.05
|
29.09
|
22.77
|
16.66
|
Announcement Date
|
28/03/19
|
20/04/20
|
26/04/21
|
24/03/22
|
30/03/23
|
28/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,008
|
2,795
|
2,962
|
3,138
|
3,506
|
3,538
|
EBITDA
1 |
645.1
|
608.3
|
526.7
|
443.2
|
624.7
|
525.4
|
EBIT
1 |
475.7
|
429.2
|
328.7
|
224
|
373.3
|
220
|
Operating Margin
|
15.81%
|
15.36%
|
11.1%
|
7.14%
|
10.65%
|
6.22%
|
Earnings before Tax (EBT)
1 |
370.1
|
315.2
|
-425.4
|
196.6
|
346
|
225.4
|
Net income
1 |
263.9
|
203.3
|
-488.8
|
108
|
273.4
|
174.7
|
Net margin
|
8.77%
|
7.27%
|
-16.5%
|
3.44%
|
7.8%
|
4.94%
|
EPS
2 |
0.6700
|
0.5200
|
-1.260
|
0.2800
|
0.7100
|
0.4500
|
Free Cash Flow
1 |
-1.592
|
233.2
|
240.6
|
9.671
|
115.3
|
251.2
|
FCF margin
|
-0.05%
|
8.34%
|
8.12%
|
0.31%
|
3.29%
|
7.1%
|
FCF Conversion (EBITDA)
|
-
|
38.34%
|
45.67%
|
2.18%
|
18.46%
|
47.81%
|
FCF Conversion (Net income)
|
-
|
114.73%
|
-
|
8.96%
|
42.19%
|
143.79%
|
Dividend per Share
2 |
0.2500
|
0.2000
|
0.2018
|
0.1982
|
0.1500
|
0.2000
|
Announcement Date
|
28/03/19
|
20/04/20
|
26/04/21
|
24/03/22
|
30/03/23
|
28/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
205
|
370
|
487
|
329
|
208
|
471
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.59
|
233
|
241
|
9.67
|
115
|
251
|
ROE (net income / shareholders' equity)
|
7.04%
|
5.24%
|
-12.7%
|
3.56%
|
8.05%
|
5.2%
|
ROA (Net income/ Total Assets)
|
5.83%
|
4.93%
|
3.88%
|
2.72%
|
4.2%
|
2.34%
|
Assets
1 |
4,522
|
4,123
|
-12,604
|
3,963
|
6,503
|
7,461
|
Book Value Per Share
2 |
10.20
|
10.40
|
8.870
|
8.840
|
9.420
|
9.680
|
Cash Flow per Share
2 |
1.840
|
2.540
|
2.780
|
2.560
|
2.240
|
2.670
|
Capex
1 |
350
|
362
|
272
|
376
|
374
|
343
|
Capex / Sales
|
11.63%
|
12.94%
|
9.2%
|
11.99%
|
10.66%
|
9.69%
|
Announcement Date
|
28/03/19
|
20/04/20
|
26/04/21
|
24/03/22
|
30/03/23
|
28/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +12.97% | 986M | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|